Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679624 · ClinicalTrials.gov registry record · Phase 2
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03679624 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 1 participants.
The verdict
NCT03679624, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts. Cohort A will comprise of ibrutinib naïve WM patients. Patients in this cohort may be treatment naïve or relapsed but who remain ibrutinib naïve. Cohort B will comprise of patients who are currently receiving ibrutinib but whose response to treatment has plateaued. In this cohort, daratumumab will be added on to ibrutinib in an attempt to deepen response.
Interventions
- DRUG Daratumumab
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2020-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03679624
The ClinicalTrials.gov registry entry for NCT03679624 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Daratumumab is the first listed.
NCT03679624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03679624 about?
NCT03679624 is a clinical study titled "Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia". This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts. Cohort A will comprise of ibrutinib naïve WM patients. Patients in this cohort may be treatment na...
What is the current status of trial NCT03679624?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-07-30. Estimated completion is 2020-10-13.
What interventions are being tested in trial NCT03679624?
The interventions under investigation include: Daratumumab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03679624?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.